Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines. Issue 8 (18th February 2020)

• Record Type: Journal Article
• Authors: Batista, Izabella Cristina Andrade; Quinan, Bárbara Resende; Rocha Alves, Érica Alessandra; Jangola, Soraya Torres Gaze; Oliveira, Eneida Santos; Colombarolli, Stella Garcia; Ferreira, Jorge Gomes Goulart; Rocha, Eliseu Soares de Oliveira; Kroon, Erna Geessien; de Assis, Rafael Ramiro; de Oliveira, Jaquelline Germano; Fiuza, Jacqueline Araújo; Calzavara-Silva, Carlos Eduardo
• Is Part Of: Vaccine. Volume 38:Issue 8(2020)
• Page Start: 2005
• Page End: 2015
• Publication Date: 2020-02-18
• Subjects: Dengue -- Tetravalent vaccine -- Chimeric proteins; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.01.003
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Dengue virus (DENV) is a Flavivirus estimated to cause 390 million infections/year. Currently, there is no anti-viral specific treatment for dengue, and efficient DENV vector control is still unfeasible. Here, we designed and produced chimeric proteins containing potential immunogenic epitopes from the four DENV serotypes in an attempt to further compose safer, balanced tetravalent dengue vaccines. For this, South American DENV isolate sequences were downloaded from the NCBI/Virus Variation/Dengue virus databases and intraserotype-aligned to generate four consensuses. Four homologous DENV sequences were retrieved using BLAST and then interserotype-aligned. In parallel, sequences were subjected to linear B epitope prediction analysis. Regions of the envelope and NS1 proteins that are highly homologous among the four DENV serotypes, non-conserved antigenic regions and the most antigenic epitopes found in the C, prM, E and NS1 DENV proteins were used to construct 11 chimeric peptides. Genes encoding the chimeric proteins were commercially synthesized, and proteins were expressed, purified by affinity chromatography and further subjected to ELISA assays using sera from individuals infected with DENVs 1, 2, 3 or 4. As a proof-of-concept, the chimeric EnvEpII protein was selected to immunize BALB/c and C57BL/6 mice strains. The immunization with EnvEpII protein associated with aluminum induced an increased number of T CD4 + and CD8 + cells, high production of IgG1 and IgG2 antibodies, and increased levels of IL-2 and IL-17 cytokines, in both mouse strains. Because the EnvEpII protein associated with aluminum induced an efficient cellular response by stimulating the production of IL-2, IL-4, IL-17 and induced a robust humoral response in mice, we conclude that it resembles an efficient specific response against DENV infection. Although further experiments are required, our results indicate that epitope selection by bioinformatic tools is efficient to create recombinant proteins that can be used as candidates for the development of vaccines against infectious diseases.